Imunon (IMNN) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Imunon is the larger company by market cap ($3.5 million vs $3.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNN | XTLB |
|---|---|---|
| Share price | $0.5355 | $1.37 |
| Market cap | $3.47M | $3.37M |
| 1-day change | -5.22% | -5.84% |
| EPS (TTM) | $-3.31 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.00K |
| Net income (latest FY) | $-14.50M | $-1.03M |
| Gross margin | — | 0.67% |
| Operating margin | — | -481.60% |
| Net margin | — | -227.72% |
| 52-week high | $4.35 | $5.64 |
| 52-week low | $0.50 | $1.37 |
| Distance from 52-week high | -87.69% | -75.71% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +3074.60% | — |
| Average volume | 150.49K | 6.58K |
| Shares outstanding | 6.49M | 2.46M |
| Employees | 20 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Imunon
IMNN stock →Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
IMNN vs XTLB FAQ
Which is bigger, Imunon or XTL Biopharmaceuticals?
Imunon (IMNN) is larger, with a market capitalization of $3.47M compared with $3.37M for XTL Biopharmaceuticals (XTLB).
Are Imunon and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.